Inactive Instrument

Peloton Therapeutics, Inc.

PLTX

US70614L1044

Biotechnology & Medical Research

Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.

April 26, 2019 at 12:00 am EDT

Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Sponsor Backed Offering

Latest news about Peloton Therapeutics, Inc.

Merck & Co., Inc. completed the acquisition of Peloton Therapeutics, Inc. from The Column Group LLC.	19-07-29	CI
Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.	19-07-10	CI
Merck & Co., Inc. signed a definitive agreement to acquire Peloton Therapeutics, Inc. from The Column Group LLC for $2.2 billion.	19-05-20	CI
Peloton Therapeutics Announces Board Changes	19-05-14	CI
Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.	19-04-26	CI
Peloton Therapeutics To Seek Acquisitions	19-04-26	CI
Peloton Therapeutics, Inc. announced that it has received $150 million in funding from a group of investors	19-02-19	CI
Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corporate Secretary	18-12-04	CI
Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer	18-08-14	CI
Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Kidney Cancer	18-06-06	CI
Peloton Therapeutics, Inc. Announces Board Changes	18-03-22	CI
Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in Patients with Advanced Kidney Cancer	17-12-20	CI
Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von Hippel-Lindau Disease-Associated Kidney Cancer	17-05-11	CI
Peloton Therapeutics, Inc. Appoints Mohammad Hirmand as Chief Medical Officer, Effective from May 1, 2017	17-04-03	CI
Peloton Therapeutics, Inc. announced that it has received $74.6 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC	17-03-13	CI
Peloton Therapeutics, Inc. announced that it expects to receive $52.4 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC	16-09-14	CI
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer	16-06-06	CI
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting	16-04-19	CI

Chart Peloton Therapeutics, Inc.

Duration

Period

More charts

Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2? (HIF-2?). HIF-2? is a transcription factor that, in part, regulates the body's response to diminished availability of oxygen. The Company's lead drug candidate, PT2977, is an oral HIF-2?. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2? is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2? inhibitor, for non-oncology indications.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs